Drug Topics
JUNE 13, 2025
Polypharmacy and potentially inappropriate medications are cited as concerns in older adults who require long-term care, especially for those with comorbidities or at multiple institutions.
PhRMA
JUNE 12, 2025
As lawmakers in Lansing debate health care legislation, new evidence reveals a staggering—and deeply troubling—reality: big, tax-exempt hospitals in the state are marking up the price of prescription medicines by nearly $10 billion a year. The federal 340B program is running unchecked with limited transparency and accountability, and comprehensive federal reform is needed to stop abuse of the program.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 6, 2025
Lauren Angelo, PharmD, MBA, associate dean of academic affairs at Rosalind Franklin University of Medicine and Science, highlights significant concerns about the evolving landscape of COVID-19 vaccine policy.
PharmaVoice
JUNE 6, 2025
Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
JUNE 11, 2025
Retail pharmacies are undergoing a meaningful transformation into accessible, community-based health care hubs by expanding clinical services, embracing value-based care, and addressing gaps in access, technology, and reimbursement.
Med Ed 101
JUNE 8, 2025
Angiotensin II receptor blockers (ARBs) are widely used in managing hypertension, heart failure, chronic kidney disease (CKD), and diabetic nephropathy. While these agents share a common mechanism—blocking the angiotensin II type 1 (AT₁) receptor—not all ARBs are created equal. As healthcare professionals, understanding the nuanced differences can guide therapy optimization, especially in patients with comorbidities […] The post Losartan Differences – A Deep Dive on ARBs appeared fir
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
PharmaVoice
JUNE 9, 2025
Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve
PhRMA
JUNE 11, 2025
The United States is the epicenter of groundbreaking biopharmaceutical research, and maintaining this leadership requires investment in the future scientific workforce. This year marks the 60th year that the PhRMA Foundation has helped build and train this workforce. A 501(c)(3) nonprofit, the Foundation provides grants and fellowships to graduate students, postdoctoral trainees and new faculty members conducting novel research, setting the stage for tomorrow’s biomedical breakthroughs tha
pharmaphorum
JUNE 10, 2025
MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus
STAT
JUNE 6, 2025
A monthly treatment from Otsuka reduced by more than half the levels of a toxic protein in the urine of patients with an autoimmune kidney disease. The results presented Friday achieved the interim goal of a Phase 3 study and were numerically superior to study results posted Monday by competitor Vera Therapeutics. The Otsuka drug, called sibeprenlimab, lowered proteinuria levels by 50.2% after nine months compared to an increase of 2.1% in patients given a placebo.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
JUNE 11, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
PharmaVoice
JUNE 10, 2025
Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.
Pharmacy Times
JUNE 13, 2025
Panelists discuss how pharmacists are essential in managing chronic graft-vs-host disease (cGVHD) by addressing challenges like toxicity, financial and logistical barriers, and a lack of awareness, while advocating for patient education, collaboration with health care teams, and ensuring access to necessary therapies.
Fierce Pharma
JUNE 9, 2025
The FDA has blessed Merck’s clesrovimab to protect against lower respiratory tract disease related to respiratory syncytial virus in newborns and infants. The monoclonal antibody, which will be known commercially as Enflonsia, will challenge Sanofi and AstraZeneca’s blockbuster Beyfortus.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
JUNE 11, 2025
Europe’s comparatively cautious approach to food additives is the envy of health secretary Robert F. Kennedy Jr. and the Make America Healthy Again movement. A Texas bill now before Gov. Greg Abbott aims to help close the gap by slapping warning labels on foods that contain any of 44 additives and dyes. Abbott has not said whether he intends to sign Senate Bill 25 into law.
Drug Topics
JUNE 9, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Pharmafile
JUNE 10, 2025
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A nephropathy (IgAN), a chronic kidney disease. The Japanese biopharma is now looking ahead to a prospective phase 3 trial of mezagitamab. The data was presented at the European Renal Association Congress on 6 June 2025 […] The post Takeda presents positive results from trial of chronic kidney disease treatment appeared first on Pharmafi
Pharmacy Times
JUNE 13, 2025
Panelists discuss how pharmacists improve patient outcomes in chronic graft-vs-host disease (cGVHD) by addressing accessibility and tolerability challenges, optimizing drug regimens, managing adherence, and fostering trust with patients to ensure consistent therapy and long-term success.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
JUNE 6, 2025
How data-driven partnerships and precision engagement are redefining pharma's role in patient care
PharmaVoice
JUNE 12, 2025
A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.
Drug Topics
JUNE 12, 2025
SF 383 prohibits PBMs from limiting patient choice of pharmacy, unfairly excluding pharmacies from networks, and forces them to reimburse pharmacies no less than what they pay affiliated pharmacies for the same drug.
STAT
JUNE 11, 2025
In December 2023, a groundbreaking announcement grabbed headlines : After years of anticipation, the Food and Drug Administration approved the first gene therapies for treating sickle cell disease, offering hope of eliminating life-altering symptoms. News at the time also featured the treatment’s prohibitive cost — between $2 and $3 million per person.
Pharmacy Times
JUNE 9, 2025
A multidisciplinary team enhances psychiatric care by empowering community pharmacists to administer long-acting injectable antipsychotics, improving patient adherence and outcomes.
Fierce Pharma
JUNE 6, 2025
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
European Pharmaceutical Review
JUNE 12, 2025
Researchers have developed a once-weekly oral capsule with an innovative delayed drug release mechanism. This development could help certain patients, such as those with schizophrenia , to take their medicines more consistently. As the drug device can be delivered orally , the new pill “represents an important option that can assist with adherence for the many patients who would prefer oral medications versus injectable formulations,” explained Leslie Citrome, a Clinical Professor of psychiatry
Drug Topics
JUNE 6, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
STAT
JUNE 9, 2025
Health secretary Robert F. Kennedy Jr. has taken the extraordinary step of firing the expert panel that advises the Centers for Disease Control and Prevention, saying the action is needed to restore faith in vaccines. “A clean sweep is needed to re-establish public confidence in vaccine science,” Kennedy said in an op-ed published Monday afternoon in the Wall Street Journal.
Pharmacy Times
JUNE 9, 2025
As policy developments unfold rapidly at both the state and federal levels, Tom Kraus highlights the expanding scope of pharmacist practice through a wave of state-level legislation as a key opportunity.
PQA
JUNE 6, 2025
Welcome to Five For Friday! Nearly 400 leaders from PQA member organizations attended the 2025 PQA Annual Meeting, May 19-21, to network, engage and gain actionable insights. Attendees heard from more than 60 speakers across the general sessions, breakout sessions, briefing sessions and innovation theaters. During the meeting, PQA presented eight Medicare plan contracts with a PQA Laura Cranston Excellence in Quality or Quality Improvement Award and awarded top posters from the 2025 PQA Annual M
Pharmafile
JUNE 10, 2025
June 10, 2025 – Lubrizol announces that an Apisolex™ polymer excipient-enabled drugformulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-basedpolymer that enhances the solubility of BCS Class II and IV active pharmaceuticalingredients (API). Apisolex polymer excipient is manufactured following GoodManufacturing Practices (GMP) guidelines and […] The post Lubrizol announces an important milestone for its novelpatent
STAT
JUNE 8, 2025
Four members of the 19-person expert panel that advises the Centers for Disease Control and Prevention on vaccination policy have been informed that their status as special government employees has been terminated — a development that throws into question their ability to continue to work on the body, STAT has learned. The Advisory Committee on Immunization Practices has been in the crosshairs of health secretary Robert F.
Pharmacy Times
JUNE 8, 2025
Ambulatory pharmacists innovate care delivery, enhancing patient access and outcomes through home visits and harm reduction clinics for complex health needs.
pharmaphorum
JUNE 13, 2025
US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by the pharma industry.
Expert insights. Personalized for you.
247 
Let's personalize your content